Blocked D Phenomenon

Why Would an RhD-Positive Baby Type as RhD-Negative?

An intrauterine transfusion can certainly complicate neonatal blood typing, particularly when donor red cells make up a substantial portion of the circulating RBC population. But there is also a rare immunohematologic explanation for an apparently D-negative newborn:

The Blocked D Phenomenon

The blocked D phenomenon can occur in a D-positive fetus or newborn affected by maternal anti-D. Maternal IgG anti-D crosses the placenta and binds to D antigen on the fetal red blood cells. When enough D antigen sites are occupied, the bound maternal antibody can interfere with the ability of routine anti-D typing reagents to react with the cells.

The result can be a false-negative or unexpectedly weak RhD type, even though the infant is genetically D-positive. This phenomenon is rare and is most often described in the setting of RhD-associated hemolytic disease of the fetus and newborn (HDFN).

A useful clue is the combination of:

• an RhD-negative mother with known anti-D,

• a newborn who unexpectedly types D-negative or gives discrepant D typing,

• evidence of HDFN, and

• a strongly positive direct antiglobulin test (DAT).

In reported cases of blocked D, the newborn's RBCs are typically heavily coated with maternal IgG anti-D and therefore demonstrate a positive DAT.

Why Does the D Typing Become Negative?

The infant's D antigen has not disappeared. Instead, maternal anti-D already bound to the neonatal RBCs can occupy or sterically interfere with D antigen sites, preventing the laboratory's anti-D reagent from producing the expected agglutination.

In other words:

The baby is D-positive, but the D antigen is temporarily being masked by maternal antibody.

An eluate prepared from the infant's RBCs may demonstrate anti-D, supporting the diagnosis of RhD-mediated HDFN.

A strongly positive DAT also complicates antiglobulin-phase testing. Tests that depend on adding anti-human globulin cannot simply be interpreted normally when the patient's RBCs are already coated with IgG.

Resolving the RhD Type

When blocked D is suspected, the laboratory may remove the antibody coating from the neonatal RBCs and then repeat D typing.

Several techniques have been reported, including gentle heat elution, acid elution, chloroquine-based methods, and glycine-EDTA treatment. After sufficient antibody removal, the DAT can be repeated and the RBCs retested with anti-D reagents. Published cases have demonstrated conversion from an apparently D-negative result before elution to clearly D-positive typing afterward.

The specific method used should follow the laboratory's validated procedure, since antibody-removal techniques differ in their ability to preserve red-cell antigens.

Where available, RHD genotyping can also help resolve an unexplained or unreliable serologic D result because it is not affected by antibody coating of the RBC surface.

Why Does It Matter?

Blocked D can create a confusing laboratory picture. An infant born to an RhD-negative mother with anti-D may appear to be RhD-negative even while showing clinical and laboratory evidence of immune hemolysis.

Recognizing the discrepancy is therefore important. Maternal antibody history, neonatal DAT results, hemoglobin, bilirubin, reticulocyte count, and other evidence of hemolysis should be considered together rather than relying on the initial RhD type alone.

When neonatal testing includes ABO/RhD typing and a DAT, unexpected results should be investigated before the RhD type is interpreted as definitive.

Importantly, blocked D itself is not an indication for exchange transfusion. Treatment is determined by the severity of HDFN—particularly the degree of anemia and hyperbilirubinemia. Severe disease may require phototherapy, RBC transfusion, or exchange transfusion. When anti-D is responsible, transfused red cells should lack the antigen corresponding to the maternal antibody and otherwise meet neonatal transfusion requirements.

Although blocked D is rare, it is an excellent example of why blood-bank results sometimes need to be interpreted in clinical and immunohematologic context rather than taken at face value.